Table 3.
Expression of CK5, ER, PR, HER2 and Ki-67 as compared in primary and metastatic tumors of 72 breast cancer patients.
| Primary positive n (%) | Recurrent/metastatic positive n (%) | P | |
|---|---|---|---|
| ER | |||
| All cases | 49 (68) | 47 (65) | 0.596 |
| Group | |||
| 1 | 9 (47) | 6 (32) | 0.083 |
| 2 | 24 (71) | 25 (47) | 0.711 |
| 3 | 16 (84) | 16 (84) | 1.000 |
| PR | |||
| All cases | 38 (53) | 24 (33) | 0.005* |
| Group | |||
| 1 | 6 (32) | 4 (21) | 0.331 |
| 2 | 19 (56) | 13 (38) | 0.110 |
| 3 | 13 (68) | 7 (37) | 0.030* |
| HER2 | |||
| All cases | 15 (21) | 15 (21) | 1.000 |
| Group | |||
| 1 | 9 (47) | 8 (42) | 0.331 |
| 2 | 5 (15) | 5 (15) | 1.000 |
| 3 | 1 (5) | 2 (11) | 0.331 |
| Ki67 | |||
| All cases | 31 (43) | 39 (54) | 0.059 |
| Group | |||
| 1 | 13 (68) | 14 (74) | 0.667 |
| 2 | 14 (42) | 21 (62) | 0.017* |
| 3 | 4 (21) | 4 (21) | 1.000 |
| CK5 | |||
| All cases | 22 (31) | 8 (11) | 0.0001* |
| Group | |||
| 1 | 11 (58) | 5 (26) | 0.010* |
| 2 | 8 (24) | 3 (9) | 0.058 |
| 3 | 3 (16) | 0 | 0.083 |
Notes: The patients are divided into Groups 1, 2 and 3, according to the time of relapse after primary diagnosis. Paired samples t-test was used. Group 1 (n = 19) includes patients with a recurrence/metastasis detected within 2 years of diagnosis. Groups 2 (n = 34) and 3 (n = 19) include patients with a recurrence/metastasis detected at 5–10 years, or after 10 years of follow-up, respectively.
*
Statistically significant